| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT05169944 Details | 2024-02-22 Interventional | 1 | - | Magrolimab Brain Neoplasms Neoplasms Recurrence Brain Cancer Brain Tumor Adu… Brain Tumor, Pe… Malignant Brain… Progressive Mal… Recurrent Brain… | FDA Partial Clinical Hold - | |||
| NCT04845035 Details | 2024-02-22 Interventional | 2 | 0 | Cytarabine Dasatinib Methotrexate Ponatinib Leukemia Leukemia, Lymph… Philadelphia Ch… Precursor Cell … Acute Lymphobla… | The PI plans to revise the study design in a new protocol - | |||
| NCT04780464 2021-000125-27 Details | 2024-02-22 Interventional | 3 | 14 | Cyclophosphamid… Doxorubicin Liposomal doxor… Prednisolone Prednisone Sarcoma Advanced Soft-t… | Withdrawal grant provider - | |||
| NCT03901573 Details | 2024-02-22 Interventional | 1/2 | 31 | Atezolizumab Carcinoma Carcinoma, Merk… Skin Neoplasms Cutaneous Squam… Melanoma Merkel Cell Car… | Strategic decision by sponsor - | |||
| NCT03461952 Details | 2024-02-22 Interventional | 2 | 4 | Ipilimumab Nivolumab Advanced Solid … | cfDNA screening data found that the prevalence of POLE/POLD1 mutations was lower than expected.
It was determined that there are no feasible options to amend this study in a fashion that
would not be duplicative of other currently accruing trials. - | |||
| NCT02865928 Details | 2024-02-22 Interventional | 4 | 42 | Bupivacaine Pain, Postopera… Augmentation Mastopexy Outpatient Brea… Revision | We decided to terminate this study due to staffing changes and other limitations posed by the
COVID-19 pandemic. - | |||
| NCT02721888 Details | 2024-02-22 Interventional | 4 | 127 | Liraglutide Diabetes Mellit… Fatty Liver Type 2 Diabetes | Failure of inclusion - | |||
| NCT05647447 Details | 2024-02-21 Interventional | 1 | 0 | SR 142801 Adenocarcinoma Hot Flashes Prostate Adenoc… | Development of the drug program has been discontinued - | |||
| NCT05607342 Details | 2024-02-21 Interventional | 1 | 1 | SR 142801 Adenocarcinoma Prostate Adenoc… | Development of the drug program has been discontinued - | |||
| NCT04624113 Details | 2024-02-21 Interventional | 1 | 13 | Pembrolizumab Carcinoma Carcinoma, Squa… Squamous Cell C… Head and Neck S… | Ipsen bought out Epizyme - | |||
| NCT04491136 Details | 2024-02-21 Interventional | 4 | 201 | Sacubitril and … Arrhythmias, Ca… Heart Failure | Company decision - | |||
| NCT04095689 Details | 2024-02-21 Interventional | 2 | - | Docetaxel Pembrolizumab Breast Neoplasm… Triple Negative… Anthracycline-r… Triple Negative… | Stopping rules met per protocol, comprehensive review needed prior to enrolling again - | |||
| NCT03374670 Details | 2024-02-21 Interventional | 2 | 0 | Aflibercept Polypoidal Chor… Vascular Diseas… Idiopathic Poly… | No patients were enrolled. Study terminated for portfolio reasons. - | |||
| NCT05934942 Details | 2024-02-20 Interventional | 1 | 29 | Drospirenone an… Healthy | Company decision - | |||
| NCT05579977 2022-002834-15 Details | 2024-02-20 Interventional | 2 | 902 | Semaglutide Diabetes Mellit… Obesity | The decision to terminate clinical development of PF-07081532 is based on pharmacokinetic data
from Phase 1 drug-drug-interaction studies and laboratory measurements of elevated
transaminases in these Phase 1 studies as well as a Phase 2 study. - | |||
| NCT05168865 Details | 2024-02-20 Interventional | 4 | 0 | Estradiol Letrozole Progesterone Abortion, Spont… Ovarian Disease… Polycystic Ovar… Frozen Embryo T… Hormone Replace… Letrozole Live Birth Miscarriage Polycystic Ovar… | unexpected slow recruitment and change of center frozen embryo transfer protocol - | |||
| NCT05060003 Details | 2024-02-20 Interventional | 2 | 7 | Atezolizumab Melanoma Stage II Melano… | Sponsor made decision to terminate study. - | |||
| NCT04984577 Details | 2024-02-20 Interventional | 2 | - | Edaravone Cerebral Infarc… Ischemia Ischemic Stroke Stroke Acute Ischemic … | Strategic realignment of sponsors. - | |||
| NCT03997448 Details | 2024-02-20 Interventional | 2 | 3 | Pembrolizumab Adenocarcinoma Gastroesophagea… | Funder decision - | |||
| NCT00456963 Details | 2024-02-20 Interventional | 4 | - | Enalapril Losartan Diabetes Mellit… Hypertension | Because of delay in approval of the protocol by a number of Ethics Commitees the trial was
terminated on March 4, 2010. No patient had received any study drug. - |